Rohto Pharmaceutical Co.,Ltd. (TYO:4527)

Rohto Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	84,771	86,816	77,161	89,210	79,951	72,791
Cash & Short-Term Investments	84,771	86,816	77,161	89,210	79,951	72,791
Cash Growth	11.78%	12.51%	-13.51%	11.58%	9.84%	37.44%
Receivables	70,870	76,847	69,880	69,115	60,656	51,682
Inventory	67,769	65,677	61,580	46,657	41,062	33,527
Other Current Assets	11,153	9,934	9,258	9,777	8,577	6,306
Total Current Assets	234,563	239,274	217,879	214,759	190,246	164,306
Property, Plant & Equipment	94,369	93,011	90,451	68,607	66,182	62,839
Long-Term Investments	58,643	58,359	46,649	43,731	32,629	27,471
Goodwill	34,216	34,242	47,494	2,285	2,564	2,954
Other Intangible Assets	49,818	49,657	8,575	6,932	6,997	6,338
Long-Term Deferred Tax Assets	-	4,154	3,975	3,869	5,371	5,297
Long-Term Deferred Charges	83	87	99	-	-	-
Other Long-Term Assets	15,459	2	2	2	1	2
Total Assets	487,151	485,771	421,875	346,175	309,677	274,627

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	23,359	22,646	22,056	21,123	18,718	16,269
Accrued Expenses	24,650	26,879	24,364	25,720	24,362	19,354
Short-Term Debt	22,145	24,742	7,035	5,304	4,177	8,033
Current Income Taxes Payable	4,431	6,911	6,963	6,643	6,230	3,185
Other Current Liabilities	33,629	36,171	34,190	28,297	26,675	24,647
Total Current Liabilities	108,214	117,349	94,608	87,087	80,162	71,488
Long-Term Debt	28,016	28,188	43,188	5,190	7,516	13,350
Long-Term Leases	7,940	7,314	-	-	-	-
Pension & Post-Retirement Benefits	2,249	707	1,770	2,548	3,104	3,332
Long-Term Deferred Tax Liabilities	-	10,767	2,081	1,597	1,173	1,450
Other Long-Term Liabilities	12,277	1,273	8,789	2,720	2,645	1,177
Total Liabilities	158,696	165,598	150,436	99,142	94,600	90,797

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	6,504	6,504	6,504	6,504	6,504	6,504
Additional Paid-In Capital	-	-	-	4,516	5,292	5,787
Retained Earnings	261,620	256,618	228,442	209,399	184,005	162,195
Treasury Stock	-9,939	-9,939	-9,939	-4,939	-4,938	-4,936
Comprehensive Income & Other	51,300	48,644	35,087	30,843	18,706	8,737
Total Common Equity	309,485	301,827	260,094	246,323	209,569	178,287
Minority Interest	18,970	18,346	11,345	710	5,508	5,543
Shareholders' Equity	328,455	320,173	271,439	247,033	215,077	183,830
Total Liabilities & Equity	487,151	485,771	421,875	346,175	309,677	274,627

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	58,101	60,244	50,223	10,494	11,693	21,383
Net Cash (Debt)	26,670	26,572	26,938	78,716	68,258	51,408
Net Cash Growth	-1.06%	-1.36%	-65.78%	15.32%	32.78%	14.58%
Net Cash Per Share	113.26	112.85	117.69	344.04	298.33	224.69
Filing Date Shares Outstanding	225.96	225.96	225.96	228.14	228.14	228.14
Total Common Shares Outstanding	225.96	225.96	225.96	228.14	228.14	228.14
Working Capital	126,349	121,925	123,271	127,672	110,084	92,818
Book Value Per Share	1369.62	1335.73	1151.04	1079.71	918.60	781.48
Tangible Book Value	225,451	217,928	204,025	237,106	200,008	168,995
Tangible Book Value Per Share	997.73	964.44	902.91	1039.31	876.69	740.75

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 17, 2026

Data Sources Report a data error